Ildong Pharmaceutical’s challenge to market with its first novel chronic hepatitis B treatment ‘Besivo’ on 1 Nov

‘Besivo,’ the Ildong Pharmaceutical’s(CEO Woong-Sup Yoon) first novel drug and the Korea’s 28^th novel drug, will be launched with the National Health Insurance benefit on 1 November. Its insurance benefit will be KRW 3,403 per tablet confirmed by the Ministry of Health and Welfare’s(MOHW) official notice. Its combination therapy with L-Carnitine will also be insured with KRW 111 per table(330mg...